69 related articles for article (PubMed ID: 2102732)
1. [The correlation between the serum levels of osteocalcin and 24,25-dihydroxyvitamin D in Paget's disease of bone].
Castro Errecarborde N; de la Piedra Gordo C; Rapado Errazti A
An Med Interna; 1990 Jun; 7(6):286-90. PubMed ID: 2102732
[TBL] [Abstract][Full Text] [Related]
2. Correlation between serum osteocalcin and 24,25-dihydroxyvitamin D levels in Paget's disease of bone.
Castro-Errecaborde N; de la Piedra C; Rapado A; Alvarez-Arroyo MV; Torres R; Traba ML
J Clin Endocrinol Metab; 1991 Feb; 72(2):462-6. PubMed ID: 1991815
[TBL] [Abstract][Full Text] [Related]
3. Alterations in vitamin D metabolites during treatment of Paget's disease of bone with calcitonin or etidronate.
Devlin RD; Gutteridge DH; Prince RL; Retallack RW; Worth GK
J Bone Miner Res; 1990 Nov; 5(11):1121-6. PubMed ID: 2125401
[TBL] [Abstract][Full Text] [Related]
4. Serum osteocalcin concentrations in Paget's disease of bone.
Wilkinson MR; Wagstaffe C; Delbridge L; Wiseman J; Posen S
Arch Intern Med; 1986 Feb; 146(2):268-71. PubMed ID: 3484940
[TBL] [Abstract][Full Text] [Related]
5. [Decrease of the coefficient of intestinal calcium absorption with normal blood levels of 1,25-dihydroxyvitamin D and decreasing levels of 24,25-dihydroxyvitamin D in Paget's disease of bone].
Traba ML; Climent P; Rapado A; de la Piedra C; Díaz Curiel M
Rev Clin Esp; 1986 Nov; 179(8):401-3. PubMed ID: 3494277
[No Abstract] [Full Text] [Related]
6. [What do we know about the significance of vitamin D in Paget's disease of the bone?].
Wilczek H; Stĕpán J; Justová V
Cas Lek Cesk; 1995 Dec; 134(24):785-7. PubMed ID: 8599821
[TBL] [Abstract][Full Text] [Related]
7. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
Torres R; de la Piedra C; Rapado A
Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor, oestrogen receptor-alpha and calcium-sensing receptor genotypes, bone mineral density and biochemical markers in Paget's disease of bone.
Donáth J; Speer G; Poór G; Gergely P; Tabák A; Lakatos P
Rheumatology (Oxford); 2004 Jun; 43(6):692-5. PubMed ID: 14997007
[TBL] [Abstract][Full Text] [Related]
9. [Osteocalcin, 24,25(OH)2D and Paget's disease].
Pérez Cano R
An Med Interna; 1990 Jun; 7(6):283-5. PubMed ID: 2102731
[No Abstract] [Full Text] [Related]
10. Paget's disease-a VDR coactivator disease?
Kurihara N; Ishizuka S; Demulder A; Menaa C; Roodman GD
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):321-5. PubMed ID: 15225793
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D in Paget's disease of bone.
Foldes J; Shamir S; Kidroni G; Menczel J
Clin Orthop Relat Res; 1989 Jun; (243):275-9. PubMed ID: 2498022
[TBL] [Abstract][Full Text] [Related]
12. Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment.
Papapoulos SE; Frolich M; Mudde AH; Harinck HI; vd Berg H; Bijvoet OL
J Clin Endocrinol Metab; 1987 Jul; 65(1):89-94. PubMed ID: 3495547
[TBL] [Abstract][Full Text] [Related]
13. [Osteocalcin].
Galli M; Caniggia M
Minerva Med; 1984 Nov; 75(42):2489-501. PubMed ID: 6334818
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D status in Paget's bone disease. Effects of calcitonin therapy.
Nunziata V; Giannattasio R; di Giovanni G; Lettera AM; Nunziata CA
Clin Orthop Relat Res; 1993 Aug; (293):366-71. PubMed ID: 8339504
[TBL] [Abstract][Full Text] [Related]
15. Calcitropic hormonal status in north Indian patients with end-stage renal disease.
Singh AK; Avula S; Kher V; Rao DS; Mithal A
Natl Med J India; 1999; 12(5):202-7. PubMed ID: 10612998
[TBL] [Abstract][Full Text] [Related]
16. [Parathyroid function in Paget's disease of bone].
Chapuy MC; Zucchelli P; Meunier PJ
Rev Rhum Mal Osteoartic; 1982 Feb; 49(2):99-102. PubMed ID: 7063800
[TBL] [Abstract][Full Text] [Related]
17. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells.
Ishizuka S; Kurihara N; Miura D; Takenouchi K; Cornish J; Cundy T; Reddy SV; Roodman GD
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):331-4. PubMed ID: 15225795
[TBL] [Abstract][Full Text] [Related]
19. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
20. [Serum osteocalcin in children with chronic renal insufficiency].
Peco-Antić A; Nastić-Mirić D; Milikić V; Babić D; Pejcić I; Kostić M; Paripović V; Jovanović O; Kruscić D; Mancić J
Srp Arh Celok Lek; 1996; 124(9-10):227-31. PubMed ID: 9102853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
